Astex Pharmaceuticals, Inc. (US)
Harold Keer is the Senior Vice President and Chief Medical Officer at Taiho Oncology, Inc. Harold also holds the title of Senior Vice President, Clinical Development at Astex Pharmaceuticals, where Harold leads Clinical Development and Regulatory groups. Previously, Harold has held prominent roles at Stanford University School of Medicine, FivePrime Therapeutics, Exelixis, Inc., and Titan Pharmaceuticals. Harold has a Doctor of Medicine (M.D.) and a Ph.D in Medicine and Tumor Cell Biology from Northwestern University.
Astex Pharmaceuticals, Inc. (US)
Astex Pharmaceuticals, Inc. (“Astex”) is committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies for the treatment of solid tumors and hematological malignancies. Astex is a member of the Otsuka group of pharmaceutical companies. The group also includes Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd and Taiho Oncology, Inc. Subject to regulatory approvals, Astex's products will be commercialized in the US and Canada by Taiho subsidiaries, and the rest of the world by Otsuka subsidiaries.